Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galapagos NV (GLPG) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Galapagos files current reports on Form 6-K, which typically furnish press releases and other information to the U.S. Securities and Exchange Commission. These reports often incorporate company announcements by reference into Galapagos’ registration statements on Form S-8, reflecting updates relevant to its equity compensation plans.
Through these filings, investors can follow how Galapagos communicates material information about its biotechnology business in oncology, immunology, inflammation, fibrosis, and other indications. The 6-Ks referenced in the record indicate that Galapagos issues press releases on topics such as clinical programs, collaborations, and corporate developments, and then submits those releases to the SEC. The filings also identify Galapagos NV as having its principal executive office in Mechelen, Belgium and clarify whether the company files under Form 20-F or Form 40-F reporting frameworks.
On Stock Titan, each new GLPG filing is captured as it becomes available from EDGAR, and AI-powered tools summarize the key points of lengthy documents. Users can quickly see what a particular 6-K press release covers without reading every page, and can navigate to the underlying exhibits for full details. Over time, this page forms a chronological record of Galapagos’ SEC reporting, helping investors review how the company’s pipeline, collaborations, and strategic decisions have been communicated to the market.
For anyone researching GLPG, this filings archive offers a structured way to examine regulatory disclosures alongside AI-generated highlights, making it easier to understand the context and content of Galapagos NV’s ongoing SEC reporting.
Galapagos NV reported full-year 2025 results and described a major strategic reset toward a business development-led model. Total net revenues rose to
The company is winding down its cell therapy activities, recording an impairment of
Galapagos NV filed a report announcing that Dr. Paulo Fontoura has been appointed by way of co-optation as a Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. He replaces Dr. Susanne Schaffert, who stepped down from the Board on November 1, 2025.
Dr. Fontoura has 20 years of pharmaceutical industry experience across neurology, immunology, ophthalmology, and rare diseases. He currently serves as Chief Medical Officer at Xaira and previously led clinical development in multiple therapeutic areas at Roche, with academic roots in neuroimmunology and ongoing teaching roles in Europe.
Galapagos reported that Bank of America Corporation crossed the 5% disclosure threshold in its shares under Belgian transparency rules. The change followed an acquisition of Galapagos voting rights and equivalent financial instruments on February 9, 2026.
As of February 11, 2026, Bank of America and affiliates held 104,522 direct voting rights and 3,415,894 equivalent financial instruments in Galapagos, representing together 5.34% of the company’s 65,897,071 outstanding shares. The notification formalizes Bank of America’s status as a significant shareholder.
Galapagos NV reports that Bank of America Corporation repeatedly crossed Belgian disclosure thresholds around 5% of its voting rights in early
Notifications show Bank of America and affiliates moving from 5.33% to 7.23%, then back down to 5.04% of Galapagos’ voting rights and equivalent financial instruments within four days.
As of
Galapagos NV submitted a Form 6-K as a foreign private issuer, confirming it files annual reports on Form 20-F. The filing states that a press release dated December 18, 2025, attached as Exhibit 99.1, has been furnished. The company also explains that the information in this Form 6-K, including Exhibit 99.1 but excluding specific quotes from Dr. Rohit Aggarwal and Henry Gosebruch, is incorporated by reference into multiple Galapagos employee share-based compensation registration statements on Form S-8.
Galapagos NV (GLPG) furnished a Form 6‑K as a foreign private issuer. The report attaches a press release dated October 23, 2025 as Exhibit 99.1 and incorporates it by reference into the company’s Registration Statements on Form S‑8.
The company indicates it files annual reports under cover of Form 20‑F. The Form 6‑K was signed by Company Secretary Annelies Denecker on October 24, 2025.